Sanofi's H1 2026 sales hit €22.1B, guidance raised, but a €952M amlitelimab impairment weighs on results
SNY is trading near its 52-week low of $40.89 (6.8% above the low).
Summary
Sanofi delivered strong H1 2026 results with 15.7% CER sales growth and raised full-year guidance, but took a €952M impairment on amlitelimab after deciding not to pursue it in atopic dermatitis.
Key Events · Earnings and Guidance · SNY
-
H1 2026 Financial Results
Net sales reached €22.1 billion, up 11.1% reported and 15.7% at constant exchange rates (CER). Business EPS came in at €3.97, a 17.1% increase versus H1 2025, while business net income rose 14.8% to €4.77 billion.
-
Full-Year 2026 Guidance Raised
Management now expects ~10% net sales growth at CER, up from a previously implied mid-to-high single digits, with business EPS growing slightly faster than sales. At July 2026 rates, currency headwinds are estimated at -1% on sales and -2% on business EPS.
-
€952M Impairment on Amlitelimab
A €952 million impairment was recorded on the amlitelimab intangible asset after the company decided not to pursue regulatory submission in atopic dermatitis, citing insufficient differentiation from standard of care. This contributed to a 30.6% effective tax rate, compared with 19.8% in H1 2025.
-
Dynavax Acquisition Completed
Dynavax Technologies was acquired on February 10, 2026 for ~$2.2 billion, adding the marketed hepatitis B vaccine HEPLISAV-B and a shingles vaccine candidate. Since the acquisition, Dynavax contributed €144 million in net sales and €89 million in business operating income.
Analysis · SNY · Life Sciences
Strong operational momentum drove Sanofi's H1 2026 results, with 15.7% CER sales growth fueled by Dupixent and new launches, and a 17.1% jump in business EPS. Reflecting that confidence, the company raised its full-year 2026 guidance to ~10% sales growth at CER, with business EPS growing slightly faster. Yet a €952 million impairment on the amlitelimab asset—stemming from the decision not to pursue regulatory submission in atopic dermatitis—dragged on reported net income and pushed the effective tax rate to 30.6%. The half-year report also details the completed Dynavax acquisition, a new CEO, and a flurry of regulatory wins and pipeline updates that reinforce the growth narrative but highlight the inherent risks of R&D portfolio decisions.
At the time of this filing, SNY was trading at $43.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $110.7B. The 52-week trading range was $40.89 to $52.68. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.